Related Experiment Video
Updated: Aug 13, 2026
02:30
Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue
Published on: October 24, 2025
Glucokinase mutations in young children with hyperglycemia
Ethel Codner1, Liyong Deng, Francisco Pérez-Bravo
1Institute of Maternal and Child Research (I.D.I.M.I.), School of Medicine, University of Chile, Santiago, Chile. ecodner@med.uchile.cl
Diabetes/Metabolism Research and Reviews
|January 31, 2006
Summary
Genetic testing for Maturity Onset Diabetes of Youth (MODY) in children with mild hyperglycemia can identify the cause and guide treatment. Identifying GCK gene mutations clarified prognosis and allowed insulin discontinuation in one family.
Area of Science:
- Pediatric Endocrinology
- Medical Genetics
- Diabetes Mellitus Research
Background:
- The cause of mild hyperglycemia without ketoacidosis in young children is often unclear.
- Maturity Onset Diabetes of Youth (MODY) is a genetic form of diabetes characterized by hyperglycemia without autoimmune beta-cell destruction.
Observation:
- Four families with young children exhibiting fasting hyperglycemia and a family history of diabetes were genetically analyzed.
- Genetic analysis focused on mutations in HNF4alpha, GCK, and HNF1alpha genes, responsible for MODY1, MODY2, and MODY3.
Findings:
- Mutations in the glucokinase (GCK) gene were identified in three of the four families studied.
- Molecular genetic characterization successfully determined the etiology and prognosis of hyperglycemia in these children.
- Insulin therapy was discontinued for one family following genetic diagnosis and clarification of the condition.
Implications:
- Molecular evaluation for MODY in children with mild fasting hyperglycemia is crucial for accurate diagnosis and prognosis.
- Genetic testing can guide therapeutic decisions and help differentiate from preclinical type 1 diabetes mellitus.
- Identifying specific MODY subtypes allows for tailored management strategies and improved patient outcomes.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...